Adverse events
PDEI showed no clear difference in adverse events compared with alpha‐blockers (low certainty).
1 finding from 1 review
Adverse events · people with myasthenia gravis
1 finding from 1 review
Side effects or other adverse events · children and adolescents with a diagnosis of autism
1 finding from 1 review
Side effects or other adverse events · children and adolescents with a diagnosis of autism
Galantamine plus risperidone may leads to higher adverse events (Side Effects Checklist) compared with placebo plus risperidone (low certainty).
1 finding from 1 review
Adverse events (all adverse events) at 26 weeks · vascular dementia and other vascular cognitive impairments
Galantamine probably leads to higher adverse events (all adverse events) at 26 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events (all adverse events) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 10 mg leads to higher adverse events (all adverse events) at 24 weeks compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 10 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 5 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events (all adverse events) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments
It is very uncertain whether rivastigmine changes adverse events (all adverse events) at 24 to 26 weeks compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (excluding deaths) at 26 weeks · vascular dementia and other vascular cognitive impairments
Galantamine showed no clear difference in serious adverse events (excluding deaths) at 26 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (excluding death) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments
Rivastigmine showed no clear difference in serious adverse events (excluding death) at 24 to 26 weeks compared with placebo (low certainty).
1 finding from 1 review
Adverse events (all reported adverse events grouped) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 5 mg showed no clear difference in adverse events (all reported adverse events grouped) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review